INDEPENDENT AUDITORS' REPORT

TO THE BOARD OF DIRECTORS AND SHAREHOLDERS OF ZYDUS DISCOVERY DMCC,

We have audited the accompanying financial statements of **ZYDUS DISCOVERY DMCC**, ("the Company") which comprise the Balance Sheet as at 31st March, 2015 and the Statement of Profit and Loss for the year ended on that date and a summary of the significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the accounting principles and the Accounting Standards generally accepted in the respective country i.e. Dubai. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our broad review. We conducted the review of these financial statements in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We have not conducted any detailed audit procedures as these financial statements have been audited by the auditors of the Company as appointed under the Laws of the Dubai in accordance with the auditing standards prevalent in Dubai. In accordance with the above, we have carried out broad review of the financial statements as submitted by the management and as audited by the auditors of the Company. We believe that our review provides a reasonable basis for our opinion. We also believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in Dubai:

- (a) in the case of the Balance Sheet, of the state of affairs of the Company as at 31st March, 2015; and
- (b) in the case of the Statement of Profit and Loss, of the loss for the year ended on that date.

Report on Other Legal and Regulatory Requirements

Further to our comments in the annexure referred to above, we report that:

- (i) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- (ii) The accounts and financial statements of the Company are duly audited and certified by the Company's Statutory Auditors viz Rao & Ross, Dubai, in accordance with the accounting and auditing standards generally accepted and prevalent in Dubai. The audited accounts along with auditors' report have been submitted to us for our review and have been appropriately verified and reviewed by us in preparing and submitting our report thereon. Our opinion is solely based on the report of the said independent auditors of the Company.
- (iii) The Balance Sheet and the Statement of Profit and Loss dealt with by this Report are in agreement with the books of account.
- (iv) In our opinion and to the best of our information and according to the explanations given to us, the said financial statements including Balance Sheet and statement of Profit and Loss dealt with by this report comply with the accounting standards generally accepted in Dubai.

- (v) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - a. The Company does not have any pending litigations which would impact its financial position.
 - b. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - c. Since the Company is incorporated outside India, this clause regarding reporting on amounts which were required to be transferred to the Investor Education and Protection Fund by the Company is not applicable.

For Mukesh M. Shah & Co. Chartered Accountants Firm Registration No. 106625W

Ahmedabad

Date: 29th June, 2015

Partner [Chandresh S. Shah] Membership No.: 042132

Particulars EQUITY AND LIABILITIES: Shareholders' Funds: Share Capital Reserves and Surplus Non-Current Liabilities: Long Term Borrowings Long Term Provisions	Note No.	USD-Thousands As at Marcl 8,014	INR-Thousand h 31, 2015
Shareholders' Funds: Share Capital Reserves and Surplus Non-Current Liabilities: Long Term Borrowings	1		
Shareholders' Funds: Share Capital Reserves and Surplus Non-Current Liabilities: Long Term Borrowings		8.014	
Share Capital Reserves and Surplus Non-Current Liabilities: Long Term Borrowings		8.014	
Reserves and Surplus Non-Current Liabilities: Long Term Borrowings			501,1
Non-Current Liabilities: Long Term Borrowings	2	(166)	
Long Term Borrowings		7,848	(10,38 490,72
Long Term Borrowings		7,040	490,7
	2	0.700	
Long Term Provisions	3	8,736	546,2
	4	1	546.2
		8,737	546,3
Current Liabilities:	_		
Trade Payables	5	533	33,3
Other Current Liabilities	6	55	3,4
		588	36,7
Total		17,173	1,073,8
ASSETS:			
Non-Current Assets:			
Fixed Assets:	7		
Tangible Assets		457	28,5
Intangible Assets		16,600	1,037,9
-		17,057	1,066,5
Long Term Loans and Advances	8	2	1
	, , , , , , , , , , , , , , , , , , ,	17,059	1,066,6
Current Assets:		17,009	2,000,0
Cash and Bank Balances	9	111	6,9
Short Term Loans and Advances	10	2	0,9
	10		
Other Current Assets	11	1	
-		114	7,1
Total		17,173	1,073,8
Significant Accounting Policies Notes to the Financial Statements	II 1 to 19		
Statement of Profit and Loss for the period e			
Particulars	Note	USD-Thousands	INR-Thousan
	No.	For the Period from March 3	
REVENUE:			1, 2015
Non Operating Revenue		-	
Total Revenue		-	-
EXPENSES:			
Employee Benefits Expense	12	64	3,9
Finance Costs	13	38	2,3
Depreciation, Impairment and Amortisation expenses	7	7	4
Other Expenses	14	57	3,4
Total Expenses		166	10,1
Loss before Tax		(166)	(10,1
Less : Tax Expenses		-	-
Loss for the year		(166)	(10,1
Basic & Diluted Earning per Share [EPS]	15	(27.64)	(1,697.
Significant Accounting Policies	II	()	(_,,
Notes to the Financial Statements	1 to 19		
· · · · · · · · · · ·			
As per our report of even date	For and	on behalf of the Board	
For Mukesh M. Shah & Co.,			
Chartered Accountants			
Firm Registration Number: 106625W			
Chandresh S. Shah Partner		Director	
Membership Number: 042132		Director	
Ahmedabad, Dated: June 29, 2015			

	Zyd	lus Discovery I	DMCC
npa	iny overview:		
		DMCC] – Dubai cal Research, Ma	5 5
nif	icant Accounting Policies:		
L	Basis of Accounting:		
-	The financial statements of the Company are prepared un accordance with the accounting principles generally accept	pted in India. Ited for the perio	al cost convention on the "Accrual Concept" of accountancy in ad starting from 15th June 2014 and ending on 31st March
2	Reporting Currency Translation:		
	Reporting currency of the Company is "USD". These acco the Company as "Non-integral operations" for holding cor for assets and liabilities using the exchange rate prevailin	mpany. The trar ng on the Balanc	translated in Indian Rupees [INR] considering the operation of slation of Financial Statements to INR from "USD" is performed e sheet date and for revenue and expenses using the average uch translation is included in "Foreign Currency Translation
3	Foreign Currency [Currency other than company's fun	ctional curren	cy] Transactions:
	Foreign currency transactions are recorded in USD at the	e approximate ra	te of exchange prevailing on the date of transactions. Foreign
	currency balances of monetary assets and liabilities are to	ranslated to USI) at the rate of exchange prevailing at the date of the
	reporting date. Gains or losses on exchange are recognise	ed in statement	of profit and loss.
ł	Fixed Assets and Depreciation:		
	a Fixed Assets are stated at historical cost less accumulated	d depreciation a	nd impairment loss.
	b Cost of each asset is depreciated over the estimated usef	ful lives on straig	ht line method, based on useful lives as below:
	Assets	Useful life	
	Office Premises	60 Years	
	Furniture and Fixtures	10 Years	
	Office Equipment	5 Years	
	Permanent Fixtures	30 Years	
	Computer and Laptop	3 Years	
	Servers and Networks	6 Years	
	c Tangible fixed assets are depreciated over the estimated the period of depreciation are consistent with the expecte to be 5% of acquisition cost by the management.		is periodically reviewed to ensure that the method and poomic benefit. Residual value of tangible assets is estimated
	d Repairs and renewals are recognised in profit or loss whe	en the expenditu	re is incurred.
	impairment. If any indication exists then the asset's reco	verable amount	orting date to determine whether there is any indication of is estimated. An impairment loss is recognised whenever the ble amount. Impairment loss is recognised in statement of
5			rees in accordance with company regulations and are in line ave and passage entitlement as a result of services rendered by
	employees up to the reporting date.		- ,
,	Borrowing Cost:		
	Borrowing costs are recognised as an expense in the year	r in which they	are incurred.
	Provisions, Contingent Liabilities and Contingent Asse	,	
	resources will be required to settle the obligation and in r liability is made when there is a possible obligation that n possible obligation or a present obligation in respect of w	respect of which may, but probab which the likeliho	result of past events and it is probable that the outflow of reliable estimates can be made. A disclosure for contingent y will not require an outflow of resources. When there is a ad of outflow of resources is remote, no provision/ disclosure is Provisions and contingencies are reviewed at each balance
	made, contingent assets are not recognised in the fillant	ent estimates.	To holding and contingencies are reviewed at each balance

sheet date and adjusted to reflect the correct management estimates.

Zydus Discovery DMCC		
Notes to the Financial Statements		
	USD-Thousands As at Marc	
Naka: 1 Shara Canitali	AS dt Mdru	11 51, 2015
Note: 1-Share Capital: Authorised:		
29,410 Shares of AED 1000/- each	8,014	501 115
29,410 Shales of AED 1000/- each	8,014	501,115 501,115
Issued, Subscribed and Paid-up:	0,014	501,115
29,410 Shares of AED 1000/- each, 100% held by Zydus Worldwide DMCC [ZWD]	8,014	501,115
	8,014	501,115
A The reconciliation of the number of Shares outstanding is as under:		
Number of shares at the beginning	-	
Add: Shares issued during the period	29,410	
Number of shares at the end	29,410	-
B The Company has only Ordinary shares. All ordinary shares rank parri passu and carry equal rights		-
with respect to voting and dividend. In the event of liquidation of the Company, the Ordinary		
shareholders shall be entitled to proportionate share of their holding in the assets remained after		
distribution of all preferential amounts.		
C Ordinary shares of AED 1000/- each, fully paid held by Holding Company, Zydus Worldwide DMCC,		
a company incorporated in Dubai, which is wholly owned subsidiary of Cadila Healthcare Ltd.,		
a company incorporated in India:		
Number of Shares	29,410	
% to total share holding	100%	
70 to total share holding	100 /0	
Note: 2-Reserves and Surplus:		
Foreign Currency Translation Reserve:		
Balance as per last Balance Sheet	-	-
Add/ [Less]: Exchange differences on translation to Indian Rupee	-	(212
	-	(212
Surplus in statement of Profit and Loss:		
Balance as per last Balance Sheet	-	-
Less: (Loss) for the period	(166)	(10,174
Balance as at the end of year	(166)	(10,174
Total	(166)	(10,386
Note: 3-Long Term Borrowings:		
Unsecured Loans [from related parties]	8,736	546,262
Total	8,736	546,262
Note: 4-Long Term Provisions:		
Provision for Employee Benefits	1	63
Total	1	63
Note: 5-Trade Payables:		
Trade Payables	533	33,328
Total	533	33,328
Noto: C. Other Current Linkilities		
Note: 6-Other Current Liabilities: Provision for Expenses	55	3,439
Total	55	3,439
		3,433

		us Discovery D the Financial S				
Note: 7-Fixed Assets:	Notes to	une rinancial S	latements			
TOLE. 7-FIXED ASSELS.			Tangible Ass	ets		Intangible Assets
	Office	Furnitures,	Office			
	Premises	Fixtures	Equipment	Computers and Networks	<u>Total</u>	Licenses
		<u>Tixtures</u>				
Current Blander			<u>USL</u>	0-Thousands		
Gross Block:					-	
As at March 31, 2014 Additions	417	34	11	2	- 464	16 60
Disposals	417	34	11	Z	404	16,600
Other adjustments					-	
As at March 31, 2015	417	34	11	2	464	16,60
Depreciation and Impairment:	117	51	11	2	404	10,00
As at March 31, 2014					-	-
Additions	5	1	1	0	7	-
Disposals	5	-	-	0	-	-
Other adjustments					-	-
As at March 31, 2015	5	1	1	0	7	-
Net Block:						
As at March 31, 2014	-	-	-	-	-	-
As at March 31, 2015	412	33	10	2	457	16,60
			INF	R Thousands		
Gross Block:						
As at March 31, 2014					-	-
Additions	26,075	2,126	688	125	29,014	1,037,99
Disposals					-	-
Other adjustments					-	-
As at March 31, 2015	26,075	2,126	688	125	29,014	1,037,99
Depreciation and Impairment:						
As at March 31, 2014					-	-
Additions	306	61	61	18	446	
Disposals					-	-
Other adjustments					-	-
As at March 31, 2015	306	61	61	18	446	
Net Block:						
As at March 31, 2014					-	-
As at March 31, 2015	25,769	2,065	627	107	28,568	1,037,99
					USD-Thousands	INR-Thousand
					As at Marc	h 31, 2015
ote : 8 - Long Term Loans and Advance	s:					
Unsecured, Considered Good]						
Security Deposits					1	6
Other Long term advances					1	6
Total					2	12
ote: 9 - Cash and Bank Balances:						
Balance with Bank					110	6,87
Cash on Hand					1	6:
Total					111	6,94
ata 10 Chart Tarra Lagua and Advant	ces :					
ote : 10 - Short Term Loans and Advand						
					2	12
Insecured, Considered Good]						
Insecured, Considered Good] Balances with Statutory authorities					2	12
Insecured, Considered Good] Balances with Statutory authorities Others [USD 40]					2	12
Jnsecured, Considered Good] Balances with Statutory authorities Others [USD 40] Total					2	
Jnsecured, Considered Good] Balances with Statutory authorities Others [USD 40] Total					2	
Jnsecured, Considered Good] Balances with Statutory authorities Others [USD 40] Total Iote: 11-Other Current Assets:						6:
Jnsecured, Considered Good] Balances with Statutory authorities Others [USD 40] Total Iote: 11-Other Current Assets: Prepaid Expenses Total					1	6:
Jnsecured, Considered Good] Balances with Statutory authorities Others [USD 40] Total Iote: 11-Other Current Assets: Prepaid Expenses Total Iote: 12-Contingent Liabilities and comm	nitments [to the exten	t not provided	for]:		1	6:
Others [USD 40] Total lote: 11-Other Current Assets: Prepaid Expenses Total lote: 12-Contingent Liabilities and comm Contingent Liabilities	nitments [to the exten	t not provided	for]:		1	6:
Jnsecured, Considered Good] Balances with Statutory authorities Others [USD 40] Total Iote: 11-Other Current Assets: Prepaid Expenses Total Iote: 12-Contingent Liabilities and comm					1	6.

		Zydus Discovery Notes to the Financial				
				For the Period from June 15,201 to March 31, 2015		
lote: 13-	Employees Benefit Expense :					
	Salaries and Wages			63	3,85	
	Gratuity			1	6:	
Total				64	3,910	
ote: 14	- Finance Cost:					
	Interest on term loan			37	2,26	
	Bank Commission & Charges			1	6:	
Total				38	2,32	
ato: 1E	Othor Exponence					
ote: 15-	-Other Expenses: Travelling expenses			1	6	
	Electricity Exps.			1	6	
	Registration expenses			4	24	
	Visa Expenses			3	18	
	Legal and Professional Fees			1		
	Fees for Incorporation			18	1,10	
	Net Loss on foreign currency transactio	ns and translation		16	97	
	Service charges - Maintenance charges			6	36	
	Miscellaneous Expenses [*]			7	42	
Total				57	3,48	
	Miscellaneous Expenses include Paymer	nt to the auditors as audit fees		2	12	
	-Calculation of Earnings per Share					
i ne ni	umerators and denominators used to ca	liculate the basic and diluted EPS are		(100)	(10.17	
	A Loss attributable to Shareholders		Thousands	(166)	(10,17	
	B Basic and weighted average number	er of shares outstanding during period		5,992	5,99	
	C Nominal value of share		AED	1,000	1,00	
	D Basic & Diluted EPS			USD (27.64)	INR (1,697.8	
	D Dasie & Diluteu Lr 5			(27.07)	(1,057.0	
ote: 17	-Related Party Transactions:					
	-Related Party Transactions: Name of the Related Parties and N	ature of the Related Party Relati	onship:			
	Name of the Related Parties and N a Holding Company:	ature of the Related Party Relati	onship:			
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC		onship:			
	Name of the Related Parties and N a Holding Company:		onship:			
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC		onship:			
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co	ompany:	onship:			
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited	ompany:	onship: Zydus Pharmaceuticals (USA) I	nc. [USA]		
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited c Fellow Subsidiaries/ Concerns:	ompany:				
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited c Fellow Subsidiaries/ Concerns: Dialforhealth India Limited	ompany:	Zydus Pharmaceuticals (USA) I	LLC [USA]		
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited c Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Unity Limited	ompany:	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA)	LLC [USA]		
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited c Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited German Remedies Limited	ompany:	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U	LLC [USA] ISA]		
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited c Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited German Remedies Limited Zydus Wellness Limited	ompany:	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U	llc [USA] ISA] ISA]		
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited c Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited German Remedies Limited Zydus Wellness Limited M/s. Zydus Wellness-Sikkim, a	ompany:	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Ltc	LLC [USA] ISA] ISA] I [South Africa]		
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited c Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited German Remedies Limited Zydus Wellness Limited M/s. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited	ompany:	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Ltc Simayla Pharmaceuticals (Pty)	LLC [USA] ISA] I [South Africa] Ltd [South Africa]		
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited c Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited German Remedies Limited Zydus Wellness Limited M/s. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited Zydus Technologies Limited	ompany: ed Partnership Firm	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Lt Simayla Pharmaceuticals (Pty) Script Management Services (P	LLC [USA] ISA] I [South Africa] Ltd [South Africa]		
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited c Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Zydus Wellness Limited M/s. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited Biochem Pharmaceutical Indus	ompany: ed Partnership Firm tries Limited	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Lt Simayla Pharmaceuticals (Pty) Script Management Services (P Zydus France, SAS [France]	LLC [USA] ISA] I [South Africa] Ltd [South Africa] ty) Ltd [South Africa]		
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited c Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Zydus Wellness Limited M/s. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited Biochem Pharmaceutical Indus Zydus BSV Pharma Private Lim	ompany: ed Partnership Firm tries Limited ited	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Lt Simayla Pharmaceuticals (Pty) Script Management Services (P Zydus France, SAS [France] Zydus Nikkho Farmaceutica Ltd	LLC [USA] ISA] I [South Africa] Ltd [South Africa] ty) Ltd [South Africa] Ia. [Brazil]		
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited c Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Greencross Limited German Remedies Limited Zydus Wellness Limited M/s. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited Biochem Pharmaceutical Indus Zydus BSV Pharma Private Lim	ompany: ed Partnership Firm tries Limited ited iership Firm	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Ltc Simayla Pharmaceuticals (Pty) Script Management Services (P Zydus France, SAS [France] Zydus Nikkho Farmaceutica Ltc Zydus Pharma Japan Co. Ltd. [LLC [USA] ISA] I [South Africa] Ltd [South Africa] ty) Ltd [South Africa] ia. [Brazil] Japan]		
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited c Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Greencross Limited German Remedies Limited Zydus Wellness Limited M/s. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited Biochem Pharmaceutical Indus Zydus BSV Pharma Private Lim M/s. Zydus Healthcare, a Partn Zydus Lanka (Private) Limited	ompany: ed Partnership Firm tries Limited ited wership Firm [Sri Lanka]	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Ltc Simayla Pharmaceuticals (Pty) Script Management Services (P Zydus France, SAS [France] Zydus Nikkho Farmaceutica Ltc Zydus Pharma Japan Co. Ltd. [Laboratorios Combix S.L. [Spai	LLC [USA] ISA] I [South Africa] Ltd [South Africa] ty) Ltd [South Africa] ia. [Brazil] Japan] n]		
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited c Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Zydus Wellness Limited M/s. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited Biochem Pharmaceutical Indus Zydus BSV Pharma Private Lim M/s. Zydus Healthcare, a Partn Zydus Lanka (Private) Limited	ompany: ed Partnership Firm tries Limited ited uership Firm [Sri Lanka] nited [Ireland]	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Ltc Simayla Pharmaceuticals (Pty) Script Management Services (P Zydus France, SAS [France] Zydus Nikkho Farmaceutica Ltd Zydus Pharma Japan Co. Ltd. [Laboratorios Combix S.L. [Spai Zydus Pharmaceuticals Mexico	LLC [USA] ISA] I (South Africa] Ltd [South Africa] ty) Ltd [South Africa] la. [Brazil] Japan] n] SA De CV [Mexico]		
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited c Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Zydus Wellness Limited M/s. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited Zydus Technologies Limited Biochem Pharmaceutical Indus Zydus BSV Pharma Private Lim M/s. Zydus Healthcare, a Partn Zydus Lanka (Private) Limited	ompany: ed Partnership Firm tries Limited ited uership Firm [Sri Lanka] nited [Ireland]	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Ltc Simayla Pharmaceuticals (Pty) Script Management Services (P Zydus France, SAS [France] Zydus France, SAS [France] Zydus Pharma Japan Co. Ltd. [Laboratorios Combix S.L. [Spai Zydus Pharmaceuticals Mexico Zydus Pharmaceuticals Mexico	LLC [USA] ISA] I (South Africa] Ltd [South Africa] ty) Ltd [South Africa] la. [Brazil] Japan] n] SA De CV [Mexico]	De C.V.[Mexico]	
	Name of the Related Parties and N a Holding Company: Zydus Worldwide DMCC b Holding Company of Holding Co Cadila Healthcare Limited c Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Greencross Limited German Remedies Limited Zydus Wellness Limited M/s. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited Biochem Pharmaceutical Indus Zydus BSV Pharma Private Lim M/s. Zydus Healthcare, a Partn Zydus Lanka (Private) Limited Zydus International Private Lim Zydus Netherlands B.V. [the Netherlands]	ompany: ed Partnership Firm tries Limited ited iership Firm [Sri Lanka] nited [Ireland] etherlands]	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Ltc Simayla Pharmaceuticals (Pty) Script Management Services (P Zydus France, SAS [France] Zydus Pharma Japan Co. Ltd. [Laboratorios Combix S.L. [Spai Zydus Pharmaceuticals Mexico Zydus Pharmaceuticals Mexico Etna Biotech S.R.L. [Italy]	LLC [USA] ISA] I [South Africa] Ltd [South Africa] ty) Ltd [South Africa] Ia. [Brazil] Japan] n] SA De CV [Mexico] Services Company SA	De C.V.[Mexico]	
	 Name of the Related Parties and N Holding Company: Zydus Worldwide DMCC Holding Company of Holding Co Cadila Healthcare Limited Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited German Remedies Limited Zydus Wellness Limited M/s. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited Biochem Pharmaceutical Indus Zydus BSV Pharma Private Lim M/s. Zydus Healthcare, a Partn Zydus Lanka (Private) Limited Zydus International Private Lim Zydus Lanka (Private) Limited Lim Zydus Netherlands B.V. [the Netherlands] ZAHL B.V. [the Netherlands] 	ompany: ed Partnership Firm tries Limited ited ership Firm [Sri Lanka] nited [Ireland] etherlands] ands]	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Ltc Simayla Pharmaceuticals (Pty) Script Management Services (P Zydus France, SAS [France] Zydus France, SAS [France] Zydus Pharma Japan Co. Ltd. [Laboratorios Combix S.L. [Spai Zydus Pharmaceuticals Mexico Zydus Pharmaceuticals Mexico	LLC [USA] ISA] I [South Africa] Ltd [South Africa] ty) Ltd [South Africa] Ia. [Brazil] Japan] n] SA De CV [Mexico] Services Company SA	De C.V.[Mexico]	
	 Name of the Related Parties and N Holding Company: Zydus Worldwide DMCC Holding Company of Holding Co Cadila Healthcare Limited Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited German Remedies Limited Zydus Wellness Limited M/s. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited Biochem Pharmaceutical Indus Zydus BSV Pharma Private Lim M/s. Zydus Healthcare, a Partn Zydus Lanka (Private) Limited Zydus International Private Lim Zydus Netherlands B.V. [the Net Zydus Netherlands B.V. [the Net Zydus Lance B.V. [the Netherlands] ZAHL Europe B.V. [the Netherlands] 	ompany: ed Partnership Firm tries Limited ited ership Firm [Sri Lanka] nited [Ireland] etherlands] ands]	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Ltc Simayla Pharmaceuticals (Pty) Script Management Services (P Zydus France, SAS [France] Zydus Pharma Japan Co. Ltd. [Laboratorios Combix S.L. [Spai Zydus Pharmaceuticals Mexico Zydus Pharmaceuticals Mexico Etna Biotech S.R.L. [Italy]	LLC [USA] ISA] I [South Africa] Ltd [South Africa] ty) Ltd [South Africa] Ia. [Brazil] Japan] n] SA De CV [Mexico] Services Company SA	De C.V.[Mexico]	
	 Name of the Related Parties and N Holding Company: Zydus Worldwide DMCC Holding Company of Holding Co Cadila Healthcare Limited Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth India Limited Dialforhealth Greencross Limited German Remedies Limited Zydus Wellness Limited M/s. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited Biochem Pharmaceutical Indus Zydus BSV Pharma Private Lim M/s. Zydus Lanka (Private) Limited Zydus International Private Lim Zydus International Private Lim Zydus Netherlands B.V. [the Net ZAHL B.V. [the Netherlands] ZAHL Europe B.V. [the Netherlands] Directors: 	ompany: ed Partnership Firm tries Limited ited ership Firm [Sri Lanka] nited [Ireland] etherlands] ands] ny]	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) LtC Simayla Pharmaceuticals (Pty) Script Management Services (P Zydus France, SAS [France] Zydus Pharmaceutical Ltd Zydus Pharma Japan Co. Ltd. [Laboratorios Combix S.L. [Spai Zydus Pharmaceuticals Mexico Zydus Pharmaceuticals Mexico Etna Biotech S.R.L. [Italy] Zydus Healthcare Philippines In	LLC [USA] ISA] I [South Africa] Ltd [South Africa] ty) Ltd [South Africa] Ia. [Brazil] Japan] n] SA De CV [Mexico] Services Company SA	De C.V.[Mexico]	
	 Name of the Related Parties and N Holding Company: Zydus Worldwide DMCC Holding Company of Holding Co Cadila Healthcare Limited Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited German Remedies Limited Zydus Wellness Limited Mys. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited Biochem Pharmaceutical Indus Zydus BSV Pharma Private Lim Mys. Zydus Lanka (Private) Limited Zydus International Private Lim Zydus International Private Lim Zydus Netherlands B.V. [the Netherlas] ZAHL B.V. [the Netherlas] ZAHL Europe B.V. [the Netherlas] Dietectors: Mr. Mukul Jain 	ompany: ed Partnership Firm tries Limited ited ership Firm [Sri Lanka] nited [Ireland] etherlands] ands] ny] Director [Ceased to be director	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Lt Simayla Pharmaceuticals (Pty) Script Management Services (P Zydus France, SAS [France] Zydus Nikkho Farmaceutica Ltd Zydus Pharma Japan Co. Ltd. [Laboratorios Combix S.L. [Spai Zydus Pharmaceuticals Mexico Zydus Pharmaceuticals Mexico Etna Biotech S.R.L. [Italy] Zydus Healthcare Philippines Ir w.e.f 31/03/2015]	LLC [USA] ISA] I [South Africa] Ltd [South Africa] ty) Ltd [South Africa] Ia. [Brazil] Japan] n] SA De CV [Mexico] Services Company SA	De C.V.[Mexico]	
	 Name of the Related Parties and N Holding Company: Zydus Worldwide DMCC Holding Company of Holding Co Cadila Healthcare Limited Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth India Limited Dialforhealth Greencross Limited German Remedies Limited Zydus Wellness Limited M/s. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited Biochem Pharmaceutical Indus Zydus BSV Pharma Private Lim M/s. Zydus Lanka (Private) Limited Zydus International Private Lim Zydus International Private Lim Zydus Netherlands B.V. [the Net ZAHL B.V. [the Netherlands] ZAHL Europe B.V. [the Netherlands] Directors: 	ompany: ed Partnership Firm tries Limited ited ership Firm [Sri Lanka] nited [Ireland] etherlands] ands] ny]	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Lt Simayla Pharmaceuticals (Pty) Script Management Services (P Zydus France, SAS [France] Zydus Nikkho Farmaceutica Ltd Zydus Pharma Japan Co. Ltd. [Laboratorios Combix S.L. [Spai Zydus Pharmaceuticals Mexico Zydus Pharmaceuticals Mexico Etna Biotech S.R.L. [Italy] Zydus Healthcare Philippines Ir w.e.f 31/03/2015]	LLC [USA] ISA] I [South Africa] Ltd [South Africa] ty) Ltd [South Africa] Ia. [Brazil] Japan] n] SA De CV [Mexico] Services Company SA	De C.V.[Mexico]	
	 Name of the Related Parties and N Holding Company: Zydus Worldwide DMCC Holding Company of Holding Co Cadila Healthcare Limited Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited German Remedies Limited Zydus Wellness Limited Mys. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited Biochem Pharmaceutical Indus Zydus BSV Pharma Private Lim Mys. Zydus Lanka (Private) Limited Zydus International Private Lim Zydus International Private Lim Zydus Netherlands B.V. [the Netherlas] ZAHL B.V. [the Netherlas] ZAHL Europe B.V. [the Netherlas] Dietectors: Mr. Mukul Jain 	ompany: ed Partnership Firm tries Limited ited ership Firm [Sri Lanka] nited [Ireland] etherlands] ands] ny] Director [Ceased to be director	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Lt Simayla Pharmaceuticals (Pty) Script Management Services (P Zydus France, SAS [France] Zydus Pharma Japan Co. Ltd. [Laboratorios Combix S.L. [Spai Zydus Pharmaceuticals Mexico Zydus Pharmaceuticals Mexico Etna Biotech S.R.L. [Italy] Zydus Healthcare Philippines Ir w.e.f 31/03/2015] w.e.f 31/03/2015]	LLC [USA] ISA] I [South Africa] Ltd [South Africa] ty) Ltd [South Africa] Ia. [Brazil] Japan] n] SA De CV [Mexico] Services Company SA	De C.V.[Mexico]	
	 Name of the Related Parties and N Holding Company: Zydus Worldwide DMCC Holding Company of Holding Co Cadila Healthcare Limited Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Dialforhealth India Limited Dialforhealth Greencross Limited German Remedies Limited Zydus Wellness Limited Mys. Zydus Wellness-Sikkim, a Liva Pharmaceuticals Limited Biochem Pharmaceutical Indus Zydus BSV Pharma Private Lim Mys. Zydus Healthcare, a Partin Zydus International Private Lim Zydus International Private Lim Zydus International Private Lim ZAHL B.V. [the Netherlas] ZAHL Europe B.V. [the Netherlas] TAHL Europe B.V. [the Netherlas] Mr. Mukul Jain Mr. Rajendra Jani 	ompany: ed Partnership Firm tries Limited ited ership Firm [Sri Lanka] nited [Ireland] etherlands] ands] ny] Director [Ceased to be director Director [Ceased to be director	Zydus Pharmaceuticals (USA) I Nesher Pharmaceuticals (USA) Zydus Healthcare (USA) LLC [U Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [U Zydus Healthcare S.A. (Pty) Lt Simayla Pharmaceuticals (Pty) Script Management Services (P Zydus France, SAS [France] Zydus Pharma Japan Co. Ltd. [Laboratorios Combix S.L. [Spai Zydus Pharmaceuticals Mexico Zydus Pharmaceuticals Mexico Etna Biotech S.R.L. [Italy] Zydus Healthcare Philippines Ir w.e.f 31/03/2015] w.e.f 31/03/2015] on 15/02/2015]	LLC [USA] ISA] I [South Africa] Ltd [South Africa] ty) Ltd [South Africa] Ia. [Brazil] Japan] n] SA De CV [Mexico] Services Company SA	De C.V.[Mexico]	

		Zyd	lus Discovery I	DMCC			
			the Financial S				
Note: 17	-Related Party Transactions - [Continu	ed]:					
	Transactions with Related Parties:	-					
	The following transactions were carried out	with the related	parties in the ord	linary course of	f business:		
	a Details relating to parties referred to in			,			
	Nature of Transactions		SD-Thousands	;		INR-Thousands	
				Year end	ed March 31, 2	<u>015</u>	
		Lielding Co. of			Lielding Co. of		
		Holding Co. of Holding Co.	Holding Co.	Fellow Subs.	Holding Co. of Holding Co.	Holding Co.	Fellow Subs.
		riolaing co.			noluing co.		
	Fixed Assets:						
	Cadila Healthcare Limited	16,600			1,037,998		
	Reimbursement of Expenses						
	Recovered:						
	Zydus Worldwide DMCC		488			29,861	
	Rent Expenses:						
	Zydus Worldwide DMCC		4			245	
	Subscription to Share Capital :						
	Zydus Worldwide DMCC		8,014			501,115	
	Finance:						
	Inter Corporate Loans received:						
	Zydus International Pvt. Ltd.			8,600		-	537,758
	Zydus Worldwide DMCC		136			8,504	
	Interest on Loan received:						
	Zydus International Pvt. Ltd.			36			2,203
	Zydus Worldwide DMCC		1			61	
	Outstanding:						
	Loan Outstanding:						
	Zydus International Pvt. Ltd.			8,600			537,758
	Zydus Worldwide DMCC		136			8,504	
	Payable:						
	Zydus International Pvt. Ltd.			36			2,251
	Zydus Worldwide DMCC		493			30,827	
	b There were no transactions with parties	referred to in ite	ms 19- A [c] &	d].	• •	· ·	
lote: 18	-Segment Information:						
	nformation on segment is not applicable as the	here are no reven	ue from operation	ons.			
lote: 19	-Previous Year figures:						
	ous year numbers are not applicable, since th	nis is the first repo	orting period.				
	Signatures to Significa	Int Accounting I	Policies and No	otes 1 to 19 to	the Financial S	Statements	
As pe	r our report of even date					behalf of the Board	
For M	ukesh M. Shah & Co.,						
Chart	ered Accountants						
Firm I	Registration Number: 106625W						
Chano	dresh S. Shah						
Partn						Director	
Parun							
	pership Number: 042132						